Skip to main content
SpringerLink
Log in

Pankreaskarzinom

Von der Molekularbiologie zu innovativen Therapien?

Pancreas cancer

From molecular biology to innovative therapies?

  • Schwerpunkt: Pankreaserkrankungen
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Die Therapie des Adenokarzinoms des Pankreas stellt ein ungelöstes Problem der modernen Medizin dar. Die molekulare Genese des Pankreaskarzinoms ist durch Mutationen in Onkogenen und Tumorsuppressorgenen sowie epigenetischen Veränderungen gekennzeichnet. Es resultiert eine Apoptoseresistenz, die zur Therapieresistenz konventioneller Zytostatika führt. Interessante therapeutische Ansatzpunkte stellen das EGFR-System und die Angioneogenese dar, da hierfür molekulare Interventionsmöglichkeiten bestehen. Weiterhin wird ein Überblick über die Studienlandschaft beim Pankreaskarzinom unter Berücksichtigung aktueller Phase-III-Studien und einiger besonders interessanter Phase-II-Studien gegeben. Die jüngsten Erfolge bei anderen chemoresistenten Tumoren berechtigen zur Hoffnung auf therapeutischen Fortschritt auch beim Pankreaskarzinom.

Abstract

Therapy for pancreatic adenocarcinoma is still one of the unsolved problems of modern medicine. The molecular genesis of pancreatic cancer is characterized by mutations in oncogenes and tumor suppressors as well as epigenetic changes. These alterations result is apoptosis resistance, which causes resistance to cytotoxic chemotherapies. Interestingly, the EGFR system and angiogenesis have been identified as therapeutic targets for which molecular therapeutic tools already exist. Here, we review current phase III trials and some phase II trials which are of particular interest. Recent success in the treatment of other tumor entities resistant to cytotoxic therapies gives hope of therapeutic progress in pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM (2004) Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J Gastrointest Surg 8: 960–969; discussion 969–970

    Google Scholar 

  2. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163: 111–116

    Google Scholar 

  3. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287–1295

    Google Scholar 

  4. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C (2005) Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54: 385–387

    Google Scholar 

  5. Hecht JR, Trarbach T, Jaeger E et al. (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol: Abstr. #3

  6. Ikeda N, Adachi M, Taki T et al. (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553–1563

    Google Scholar 

  7. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 85: 27–34

    Google Scholar 

  8. Johnson BE, Janne PA (2005) Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65: 7525–7529

    Google Scholar 

  9. Kindler HL, Friberg G, Singh DA et al. (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033–8040

    Google Scholar 

  10. Lemoine NR, Hughes CM, Barton CM et al. (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166: 7–12

    Google Scholar 

  11. Louvet C, Labianca R, Hammel P et al. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509–3516

    Google Scholar 

  12. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432: 307–315

    Google Scholar 

  13. Luo J, Guo P, Matsuda K et al. (2001) Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92: 361–369

    Google Scholar 

  14. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW (2001) Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 21: 27–44

    Google Scholar 

  15. Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Google Scholar 

  16. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227–253

    Google Scholar 

  17. Schneider G, Siveke JT, Eckel F, Schmid RM (2005) Pancreatic cancer: basic and clinical aspects. Gastroenterology 128: 1606–1625

    Google Scholar 

  18. Schulze-Bergkamen H, Krammer PH (2004) Apoptosis in cancer — implications for therapy. Semin Oncol 31: 90–119

    Google Scholar 

  19. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189: 1–7

    Google Scholar 

  20. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88: 2239–2245

    Google Scholar 

  21. von Marschall Z, Cramer T, Hocker M et al. (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119: 1358–1372

    Google Scholar 

  22. Xiong HQ, Rosenberg A, LoBuglio A et al. (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 22: 2610–2616

    Google Scholar 

  23. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565–569

    Google Scholar 

  24. Yokoi K, Sasaki T, Bucana CD et al. (2005) Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65: 10371–10380

    Google Scholar 

  25. Zhao YP, Zhang LY, Liao Q, Guo JC, Chen G, Li JY (2004) Detection of multidrug resistant gene 1 in pancreatic cancer. Hepatobiliary Pancreat Dis Int 3: 307–310

    Google Scholar 

Download references

Interessenkonflikt:

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. II. Medizinische Klinik am Klinikum rechts der Isar, Technische Universität, München

    F. Eckel, G. Schneider &  R. M. Schmid

  2. II. Medizinische Klinik am Klinikum rechts der Isar, Technische Universität, Ismaninger Straße 22, 81675, München

    R. M. Schmid

Authors
  1. F. Eckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. M. Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. M. Schmid.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eckel, F., Schneider, G. & Schmid, R.M. Pankreaskarzinom. Gastroenterologe 1, 27–33 (2006). https://doi.org/10.1007/s11377-006-0003-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-006-0003-3

Schlüsselwörter

Keywords

Search

Navigation